A new study published in the European Heart Journal has found that patients who have experienced a heart attack (myocardial ...

Heart disease remains the leading cause of death worldwide, and developing new therapeutic approaches constitutes an urgent healthcare priority. Almost one-third of patients surviving myocardial ...

A specially designed drug prevented laboratory mice from developing heart failure after heart attacks, according to new research from Cedars-Sinai. This discovery could lead to new treatments to ...

Doxazosin was recently withdrawn from this trial after ... failure (CHF). [30] There was no difference in the primary end point, fatal coronary heart disease, or nonfatal myocardial infarction ...

Heart health is central to overall well-being, so it's important to be aware of certain risk factors for heart disease and symptoms that may indicate something is wrong ...

Breast cancer survivors who developed incident myocardial infarction or heart failure exhibited increased risk for adverse oncologic outcomes, according to a population-based cohort study.The findings ...

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

SGLT-2 inhibitors canagliflozin, empagliflozin, and dapagliflozin showed overall comparable effectiveness on cardiovascular outcomes in T2D.

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

Summary: Heart failure is a clinical syndrome characterized ... cardiac hypertrophy, myocardial fibrosis, ventricular arrhythmias, and ischemic and necrotic lesions. There are currently two ...